Proof-of-concept study on the effects of 10 mg fampridine (oral administration) on working memory in healthy participants.
The hypotheses is that fampridine improves working memory performance.

开始日期2040-01-01

申办/合作机构

University of Basel

[+1]

NCT05688241

/ Not yet recruiting临床1/2期IIT

Epstein-Barr Virus (EBV) -Specific T Memory Stem Cell (Tscm) Therapy to Treat EBV- Driven Lymphomas/ Diseases

In this multi-center open-label, non-randomized phase I/II intervention study three consecutive doses of donor-derived EBV Tscm-CTLs will be administered to 10 patients with treatment-refractory EBV lymphoma, diseases or PTLDs. EBV Tscm-CTLs will derive from hematopoietic cell transplant (HCT) or third-party donors.

开始日期2026-11-01

申办/合作机构

Universitätsspital Basel

NCT07166549

/ Not yet recruiting临床1期IIT

A Phase I Trial of Bispecific Anti-CD19, Anti-CD20 CAR T Cells for B Cell Malignancies

This study is to provide locally produced, bispecific CD19 CD20 CAR T cells to patients with B-cell lymphoma/leukemia who have no access to commercial CAR T cells or who have relapsed thereafter. The primary objective is to assess the safety of bispecific anti-CD19, anti- CD20 CAR T cell-therapies after lymphodepleting chemotherapy in patients with B cell malignancies with exhausted standard treatment options.

开始日期2026-06-01

申办/合作机构

Universitätsspital Basel

100 项与 University of Basel 相关的临床结果

登录后查看更多信息

0 项与 University of Basel 相关的专利（医药）

登录后查看更多信息

39,763

项与 University of Basel 相关的文献（医药）

2026-12-31·European Journal of Psychotraumatology

Understanding the developmental impact of psychological maltreatment through the lens of the dimensional model of adversity and psychopathology

Article

作者: Beck, Katharina ; Wallimann, Meret Sophie ; Lätsch, David Cyrill

Background: Psychological maltreatment is linked to negative developmental outcomes in adolescents. It includes psychological abuse (PA) and psychological neglect (PN), which are commonly studied as a pair. This study applied the dimensional model of adversity and psychopathology (DMAP), which conceptualises abuse as a threatening experience involving harm or the threat of harm that primarily impairs social-emotional processing, such as emotion regulation, while it views neglect as deprivation or absence of parental care that predominantly affects cognitive functioning, such as working memory.Objective: In an effort to better understand the harmful nature of psychological maltreatment, this study applies the DMAP to understand whether PA and PN have differential effects paving divergent trajectories to psychopathology, hypothesising that PA predicts dysfunctional emotion regulation, whereas PN impairs working memory.Method: A classroom-based online survey was conducted in Switzerland. The analysis incorporated a sample size of 1,207 adolescents across 82 classes. PA, PN, and dysfunctional emotion regulation were assessed using self-report, and working memory was assessed using a performance task. Hierarchical linear regression models were conducted with controls for co-occurring deprivation, threat, and other individual and family factors (e.g. socioeconomic status, attention deficit hyperactivity disorder) at level 1, and for education level and the trauma load of the school class at level 2.Results: In modelling dysfunctional emotion regulation, PA (β = 0.45, p < .001) was the strongest predictor, whereas PN had no significant effect. In the working memory model, neither PN nor PA was significantly predictive.Conclusion: These findings partially support the DMAP framework, underscoring psychological abuse as an important factor in dysfunctional emotion regulation and psychopathology.

2026-12-01·Journal of Sport and Health Science

Intensity modifies the association between continuous bouts of physical activity and risk of mortality: A prospective UK Biobank cohort analysis

Article

作者: Henson, Joe ; Razieh, Cameron ; Goldney, Jonathan ; Yates, Tom ; Khunti, Kamlesh ; Davies, Melanie ; Zaccardi, Francesco ; Kingsnorth, Andrew P ; Schwendinger, Fabian ; Rowlands, Alex V

BACKGROUND:

Recent evidence suggests continuous bouts of physical activity (PA) are associated with longevity. We hypothesized the risk of mortality would be lower when the most active minutes of the day were in a continuous bout.

METHODS:

PA was assessed using accelerometery in UK Biobank participants. The intensity of the most active continuous (MX_CONT) and accumulated (MX) X min of the day, and their ratio (MX_RATIO = MX_CONT/MX), were determined. MX_RATIO indicates how the most active minutes of the day are accumulated, ranging from a single continuous bout through to sporadic accumulation spread across the day. Durations (X) considered ranged from 1 to 20 min. The outcome was mortality.

RESULTS:

In total, 94,541 participants (56.5% female) were included. Over a median (interquartile range) follow-up of 6.9 (6.3, 7.4) years, 2649 (2.8%) deaths occurred. Intensity moderated the association between how the most active minutes of the day were accumulated and mortality risk, expressed relative to sporadically accumulated moderate PA. If the most active minutes were of moderate intensity, the risk of mortality was halved for continuous compared to sporadic accumulation, irrespective of duration; if the most active minutes were of vigorous intensity, a continuous bout was associated with the lowest risk for durations under 5 min (e.g., 3 min: hazard ratio (HR) = 0.27, 95% confidence interval (95%CI): 0.21-0.34), while sporadic accumulation was associated with the lowest risk for durations beyond 5 min (HR = 0.11, 95%CI: 0.08-0.15 for the most active 20 min).

CONCLUSION:

Optimal PA patterns for reducing mortality differ by intensity and duration. For moderate-intensity PA, a lower mortality risk may be optimized by prioritizing continuous PA for up to 20 min. However, for vigorous-intensity PA, multiple short bouts (<5 min) may be optimal. This suggests tailored PA recommendations may enhance longevity benefits.

2026-06-01·Global epidemiology

On misconceptions about the Brier score in binary prediction models

Article

作者: Hoessly, Linard

The Brier score is a widely used metric in epidemiological and clinical research for evaluating the accuracy of probabilistic predictions for binary outcomes, such as disease occurrence, treatment response, and screening performance. Despite its popularity, the Brier score is frequently misunderstood, leading to flawed interpretation of prediction models and potentially misguided public health and clinical decisions. This study aims to didactically clarify common misconceptions about realised Brier scores and to provide practical, statistically rigorous guidance for its correct interpretation in epidemiologic and public health prediction models. We analytically examined its statistical properties and conducted simulation studies across diverse scenarios, varying the distribution of true outcome probabilities, prediction accuracy, sample size, and event prevalence. Five prevalent misconceptions were identified, including the mistaken belief that a Brier score of zero indicates a perfect model. Analytic arguments and simulations demonstrated that even perfectly specified models yield non-zero Brier scores under realistic conditions. The Brier score was shown to reflect not only prediction accuracy but also the underlying distribution of true risks and random variation in outcomes. Comparisons across different populations or disease settings can therefore be misleading, and the Brier score does not directly measure calibration. We recommend restricting comparisons to the same population and complementing the Brier score with calibration metrics and measures of clinical or public health utility. Adopting these practices will improve the validity and interpretability of risk prediction in epidemiologic research and enhance decision-making in population health.

237

项与 University of Basel 相关的新闻（医药）

2026-02-05

·drugs

Cardiologist Evaluation Beneficial in Perioperative Myocardial Infarction/Injury

THURSDAY, Feb. 5, 2026 -- For patients with perioperative myocardial infarction /injury (PMI) after undergoing noncardiac surgery, cardiologist evaluation is associated with a reduced risk for major adverse cardiac events and all-cause death at one year, according to a study published online Jan. 30 in the European Heart Journal . Noemi Glarner, M.D., Ph.D., from University Hospital Basel in Switzerland, and colleagues conducted a multicenter prospective study involving high-risk patients undergoing noncardiac surgery who were eligible for PMI active surveillance. Patients with PMI receiving a cardiologist evaluation were compared to those not receiving evaluation. Major adverse cardiac events, defined as a composite of cardiovascular death, myocardial infarction, acute heart failure, and life-threatening arrhythmia at 365 days, were examined as the primary end point. Of the 14,294 patients, 1,048 developed PMI and were eligible for analysis; 58.6 percent received postoperative cardiologist evaluation. The researchers found that cardiologist evaluation was independently associated with a lower risk for major adverse cardiac events and all-cause death after adjustment (adjusted hazard ratios, 0.54 and 0.65, respectively) at 365 days. These findings were confirmed in sensitivity analyses. The likelihood of undergoing noninvasive cardiac imaging and receiving dual antiplatelet and statin therapy was increased among patients receiving cardiologist evaluation. "Surgery is only carried out for good reason and following careful assessment of the risks, but complications do still occur. It's vital to screen for PMI in patients who are at risk. Where signs of heart injury are found, a cardiologist can ensure patients get the monitoring and treatment they need," Glarner said in a statement. Several authors disclosed ties to biopharmaceutical companies, including Abbott Diagnostics, Roche, AstraZeneca, and Boehringer Ingelheim, which partially funded the study. Abstract/Full Text Editorial

AHA会议临床研究

2026-02-04

·小红书

💊 巴塞尔大学药物科学博士

📍 瑞士｜研究型大学｜生命科学与制药研究重镇 University of Basel（巴塞尔大学）在药物科学（Pharmaceutical Sciences）× 药物研发 × 分子药理与转化医学研究方向博士培养体系成熟，与欧洲制药产业联系极紧密，基础研究与临床应用结合度高，长期稳定招收研究型 PhD，国际博士比例高，英文科研环境成熟。 📌 博士研究方向 • 药物科学（Pharmaceutical Sciences） • 药物发现与分子设计 • 药理学与毒理学研究 • 药物递送系统与纳米药物 • 转化医学与疾病靶点研究 🧪 科研环境 • 博士主要分布在生命科学学院与药学研究中心 • 实验导向极强，强调机制研究与药物功能验证 • 博士以独立研究为主，常嵌入国际药企合作项目 • 国际合作密集，科研成果转化能力突出 💰 资助情况 • 瑞士博士为正式受雇研究人员 • 学费全免 • 固定高薪资（瑞士博士薪酬体系） • 社会保险与科研经费齐全 • 合同期通常 3–4 年 🎯 适合背景 • 药学 / 生物医学 / 分子生物学 • 化学 / 生物工程相关背景 • 有实验研究与药物开发经验者优势明显 📌 申请提示 • 以研究方向匹配度 + 实验能力 + 导师契合度为核心 • Proposal 建议明确：疾病靶点、药物机制与实验验证路线 • 有科研论文、实验项目或制药相关经验非常加分 👉如果你想了解巴塞尔大学的药物科学博士和你的背景是否匹配,👇戳我,为你快速评估[自拍R][自拍R][自拍R]#博士申请 #全奖读博士 #PhD申请 #生物医学科研 #药学 #博士留学 #医学 #生物与医药 #药企 #医学博士

2026-01-22

·drugs

Community Water Fluoridation Not Linked to Adverse Birth Outcomes

THURSDAY, Jan. 22, 2026 -- Community water fluoridation (CWF) is not associated with adverse birth outcomes, according to a study published online Jan. 20 in JAMA Network Open . Benjamin Krebs, Ph.D., from the University of Basel in Switzerland, and colleagues conducted a cohort study to examine the association between prenatal exposure to CWF and birth outcomes using an event-study analysis with a difference-in-differences approach, exploiting the staggered rollout of CWF from January 1968 to December 1988 across U.S. counties. The sample included 11,479,922 singleton births across 677 counties (408 CWF-treated [60.3 percent] and 269 never treated [39.7 percent]) during the 21-year period. The researchers found no evidence of an association for CWF with birth weight or other birth outcomes. No discernible pretreatment trends were seen, and there were no significant changes after adoption of CWF, with estimates of small magnitude seen across all posttreatment periods, ranging from −8.44 to 7.20 g. Sensitivity analyses incorporating state-specific time trends, alternative exposure thresholds, and tests for compositional changes in births supported these findings. "CWF is not associated with infant health as measured by birth weight, contributing to ongoing evaluations of the safety of CWF, particularly with regard to potential adverse effects during pregnancy," the authors write. Abstract/Full Text

临床结果

100 项与 University of Basel 相关的药物交易

登录后查看更多信息

100 项与 University of Basel 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2026年02月08日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

临床前

临床1期

临床2期

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

Fexinidazole sulfone	利什曼病更多	临床2期
EBV-Tscm Cytotoxic T Cells(University Hospital, Basel)	EBV 相关的移植后淋巴增殖性疾病更多	临床1/2期
镥[177Lu]依多曲肽 ( SSTR )	脑膜瘤更多	临床1/2期
Anti-CD19, Anti-CD20 CAR T Cells(Universitätsspital Basel) ( CD19 x CD20 )	边缘区B细胞淋巴瘤更多	临床1期
2,5-Dimethoxy-4-bromophenethylamine ( 5-HT2A receptor x 5-HT2B receptor x 5-HT2C receptor )	难治性抑郁症更多	临床1期